Recently, the Beijing Municipal Health Commission announced the top ten achievements of the "Capital Health Development Research Project" (abbreviated as "CHDR Project") from 2012 to 2022 at the Public Health Summit Forum of the China International Fair for Trade in Services 2023. After multiple rounds of assessment, the "Analysis and Assessment System of Fractional Flow Reserve Based on Coronary Angiography" project, led by Professor Jianping Li from Peking University First Hospital, stood out and was awarded one of the top ten achievements of the "CHDR Project." It was showcased on the world's only national-level international comprehensive service trade platform. The research technology of the "Analysis and Assessment System of Fractional Flow Reserve Based on Coronary Angiography" project is from caFFR system domestically developed by RainMed Medical, which can accurately measure coronary blood flow without pressure wires and hyperemic agents, and assist operators in achieving precise diagnosis and treatment of coronary artery disease.

The "CHDR Project" was established in 2011 and is a project under the jurisdiction of the Beijing Municipal Health Commission aimed at promoting sustainable and coordinated development of the capital's medical and health industry, comprehensively improving medical and health service capabilities, and improving disease prevention and treatment levels. To systematically evaluate and summarize the research results and experience of the "CHDR Project" over the past 10 years, the Beijing Municipal Health Commission launched a 10-year achievement investigation, delving into representative projects in terms of achievement transformation, paper publication, and award-winning. After a rigorous selection process, the "Analysis and Assessment System of Fractional Flow Reserve Based on Angiography" project led by Professor Jianping Li's team from Peking University First Hospital was successfully selected. This recognition demonstrates the leading and exemplary role of RainMed Medical's caFFR system in the precise diagnosis of coronary artery disease and its clinical promotion, which has gained high recognition from government departments, experts and scholars.

Coronary artery functional assessment is the gold standard for evaluating myocardial ischemia and guiding coronary artery blood flow reconstruction. However, traditional coronary artery functional assessment methods (pressurewire-derived FFR) require the use of pressure wires and hyperemic agents, which have complex operation procedures, high costs, and high risks, leading to limited clinical application scenarios. Based on the functional analysis technology of coronary angiography (RainMed Medical's caFFR system), it does not require pressure wires and hyperemic agents. There are no additional surgical operations. The FFR value can be measured in an average of 5 minutes through two angiograms and the real-time aortic pressure, which is safer, more efficient and convenient. It is an advanced diagnostic technology that has gained high attention from international experts and scholars.

Since 2016, Professor Jianping Li has led the cardiovascular department team to collaborate with RainMed Medical in exploring and validating the clinical value of non-invasive coronary artery functional assessment tools. They have developed the caFFR system, a non-invasive functional assessment tool derived from angiography with complete independent intellectual property rights and validation based on Chinese population data.

Scientific diagnosis is the foundation of precision medicine. The research team has conducted multiple validations of the clinical accuracy of the caFFR system, all of which have shown a diagnostic accuracy of over 90%. In prospective and multicenter clinical studies, the caFFR system was compared with pressurewire-derived FFR, demonstrating a diagnostic accuracy of 95.7% in detecting myocardial ischemia , a high sensitivity and specificity of 90.4% and 98.6% respectively. The positive predictive value and negative predictive value were as high as 97.2% and 95.0% respectively. This research has been accepted by internationally renowned SCI journals such as "Cardiovascular Research" and "Catheterization and Cardiovascular Interventions", and has obtained seven related invention patents.

As one of the most accurate innovative coronary artery functional diagnostic technologies, the caFFR system has taken the lead in establishing marketing layouts both domestically and internationally, breaking through the zero export of domestic FFR systems. Currently, the caFFR system has obtained 3 heavyweight medical device registration certificates from China NMPA, EU CE, and Australia TGA. The product has covered over 1,100 hospitals in 30 provinces, municipalities, and autonomous regions in China. It has been included in the medical insurance reimbursement list of 25 provinces and regions and exported to 15 countries and regions overseas. Its sales volume is leading other similar products, greatly promoting the clinical popularization of coronary artery functional evaluation and bringing high-quality diagnosis and treatment services to patient with coronary artery diseases globally.

RainMed Medical cherishes and values the honor of being selected as one of the top ten achievements of the "CHDR Project." It will not forget its original intention of benefiting the majority of patients with vascular diseases, continue to deepen its precision diagnosis and treatment of vascular diseases, continuously explore future medical innovation paradigms, and continuously launch revolutionary innovative products to contribute to the development of precision medicine!